While immunotherapies have revolutionized the treatment of cancer, the large majority of patients with solid tumours still do not respond to them. Neobe is developing a platform for the engineering of programmable live biotherapeutics, which can colonize solid tumours and remodel their local microenvironment. By removing barriers to immune infiltration in a safe and localized way, Neobe’s recombinant live biotherapeutics can potentially double the number of cancer patients that respond to existing immunotherapeutic strategies.